DE69131513D1 - Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon - Google Patents

Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon

Info

Publication number
DE69131513D1
DE69131513D1 DE69131513T DE69131513T DE69131513D1 DE 69131513 D1 DE69131513 D1 DE 69131513D1 DE 69131513 T DE69131513 T DE 69131513T DE 69131513 T DE69131513 T DE 69131513T DE 69131513 D1 DE69131513 D1 DE 69131513D1
Authority
DE
Germany
Prior art keywords
gag
vaccinia
addition
particles
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131513T
Other languages
English (en)
Other versions
DE69131513T3 (de
DE69131513T2 (de
Inventor
Hans Wolf
Holger Fliessbach
Brunn Albrecht Dr V
Ralf Wagner
Manfred Motz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thermo Fisher Scientific Geneart GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8203785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69131513(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of DE69131513D1 publication Critical patent/DE69131513D1/de
Application granted granted Critical
Publication of DE69131513T2 publication Critical patent/DE69131513T2/de
Publication of DE69131513T3 publication Critical patent/DE69131513T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69131513T 1990-03-21 1991-03-21 Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon Expired - Fee Related DE69131513T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90105319 1990-03-21
EP90105319 1990-03-21

Publications (3)

Publication Number Publication Date
DE69131513D1 true DE69131513D1 (de) 1999-09-16
DE69131513T2 DE69131513T2 (de) 2000-05-04
DE69131513T3 DE69131513T3 (de) 2005-05-25

Family

ID=8203785

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131513T Expired - Fee Related DE69131513T3 (de) 1990-03-21 1991-03-21 Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon

Country Status (5)

Country Link
EP (1) EP0449116B2 (de)
AT (1) ATE183235T1 (de)
DE (1) DE69131513T3 (de)
ES (1) ES2140380T5 (de)
GR (1) GR3031817T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773211A (en) * 1991-07-10 1998-06-30 Abbott Laboratories Differentiation of HTLV-I and HTLV-II using synthetic peptides
GB9208218D0 (en) * 1992-04-14 1992-05-27 British Bio Technology Hybrid particles
EP0565794A1 (de) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induktion von CTL-Antworten
ATE199394T1 (de) * 1992-06-04 2001-03-15 Univ Osaka Res Found Gag-env fusion-antigen aus hiv
AU6829494A (en) * 1993-08-02 1995-02-28 Chiron Corporation Recombinant constructs using replacement sequences in hypervariable regions
ATE288488T1 (de) * 1997-03-11 2005-02-15 Mayo Foundation Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
ES2299276T3 (es) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
CA2419822C (en) * 2000-08-14 2011-02-08 Gary J. Nabel Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
EP2280074A3 (de) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (de) 2001-08-31 2006-04-26 Chiron Corp Antigene hiv-typ-b-polypeptide codierende polynukleotide, polypeptide und verwendungen davon
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
EP1814583A2 (de) 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Kombinationswege zur erzeugung von immunantworten
US8620059B2 (en) 2007-12-13 2013-12-31 Fpinnovations Characterizing wood furnish by edge pixelated imaging
US20140004146A1 (en) * 2011-03-17 2014-01-02 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Method for producing virus-like particle by using drosophila cell and applications thereof
RU2609769C2 (ru) 2011-04-06 2017-02-02 Биоваксим Лимитед Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей
WO2015193143A1 (en) 2014-06-18 2015-12-23 Morphosys Ag Fusion proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
EP0343132B1 (de) * 1988-05-06 1994-08-17 Ferropas Ag Verfahren und Systeme zur Herstellung von HIV-Antigenen

Also Published As

Publication number Publication date
DE69131513T3 (de) 2005-05-25
ES2140380T5 (es) 2005-03-16
ATE183235T1 (de) 1999-08-15
EP0449116B2 (de) 2004-08-25
ES2140380T3 (es) 2000-03-01
DE69131513T2 (de) 2000-05-04
EP0449116A1 (de) 1991-10-02
EP0449116B1 (de) 1999-08-11
GR3031817T3 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
DE69131513D1 (de) Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon
Lipka et al. Segregation of human T cell lymphotropic virus type I and II infections by antibody reactivity to unique viral epitopes
US5580773A (en) Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
US5550052A (en) Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type cells
Strand et al. Structural proteins of mammalian oncogenic RNA viruses: immunological characterization of the p15 polypeptide of Rauscher murine virus
JPS62244393A (ja) Ｈｔｌｖ−３ｇａｇ／ｅｎｖ遺伝子蛋白質の発現と精製
EP0602046B2 (de) Detektion des immunschwäche-virus aus felis
ATE297984T1 (de) Mit hiv-2 infizierte menschliche t-zelllinie die funktionell intaktes hiv-2 gp160 sekretiert
WO1992016556A1 (en) Derivatives opf gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
KR0172970B1 (ko) Aids백신에 유용한 키메릭 단백 및 그의 제조방법
Laurent et al. Cell surface expression of several species of human immunodeficiency virus type 1 major core protein
ATE87487T1 (de) Rekombinante hiv-2 polypeptide.
AU654970B2 (en) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
DE3850593T2 (de) Synthetische Antigene zur Bestimmung der AIDS-bezogenen, von LAV-2 verursachten Krankheiten.
Bugge et al. Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody
Marin et al. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus
WO1988008449A1 (en) Hiv related human retrovirus strain with cloned nucleotide sequence and applications thereof
Edouard et al. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
JPS63254983A (ja) エイズの病原であるウイルスのｐ２５蛋白質をコードするウイルスベクター及び組換ＤＮＡ、感染された細胞培養物、得られる蛋白質、ワクチン及び得られる抗体
DUBOIS et al. Expression and purification of protein segments encoded by the envelope and 3′-orf genes of human immunodeficiency virus type 1
Schupbach et al. Detection of high concentrations of HTLV‐1 p24 and a novel gag precursor, p45, in serum immune complexes of a healthy seropositive individual
CA2084136A1 (en) Design, construction and expression of chimeric proteins for development of vaccines and diagnostic reagents
JPH01502659A (ja) Ｔ−４レセプターへの結合を阻害し免疫原として作用する小ペプチド類
Hitchcock Molecular localization of conformation-dependent B cell epitopes of the major core protein (p24) of human immunodeficiency virus
JPH01148183A (ja) 組み換えワクチニアウイルス

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: GENEART GMBH, 93053 REGENSBURG, DE

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: GENEART AG, 93053 REGENSBURG, DE

8339 Ceased/non-payment of the annual fee